Clinical Trial Update: A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the safety of administering rituximab at a more rapid infusion rate in patients with rheumatoid arthritis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED | Results posted: 2014-02-19